Member Info for Badsterman

Great post Sean,

Did you discuss the financial viability of the lab? Is the work mostly for internal projects, or external suppliers paying for services?

I realise Valirx can't disclose commercial deals but your viewpoint would be interesting? 👍

I've made these points before;

1. It took Amazon NINE years to turn a profit, why do some posters expect instant success?

2. Not every portfolio company will succeed, you've got to be prepared for at least one failure.

What Cliff has achieved, by getting four University ideas to fully fledged businesses, is very impressive.

I understand the negativity, but;

LUCY up from lows with Reebok launch imminent.

SALT holding around 90p, still twice the IPO price.

BELL recently issued some very upbeat sales guidance.

We await news on Guident, Revive and the AI project.

It's not all doom and gloom, is it?

Zak Mir quotes "when this share moves, it really moves"

(Forward to 11:35)

https://youtu.be/F0e0DMC1lfo

Also some candles and moving averages hocus-pocus. 🤣

Great find Northern,

Last time I checked, Toby was on another jolly in Dubai.

Looks they've raised the cash and are taking 401 forward, hence the need for a MAB.

👍

EUDA...and up 7.34% as I write.

https://tinyurl.com/8k2k4m4t

Watching England is more exciting than Valirx. 🙄

Baz,

Whatever your view of Cliff, the vote is a thumping majority for his leadership.

Marvellous news, I'll get the first round in🥂🍻🍹

TEK's major stake, 77% in SALT, cannot be realised until Feb 2025 due to a condition of the IPO.

Neither Bell or Lucy are generating profit, both are following a raise and spend pattern. That said, each have deals, partnerships and contracts up and running, plus they are manufacturing and selling patented products.

Guident, Revive and the AI project are difficult to value accurately.

IMHO most investors are waiting for a game changing RNS e.g. SALT landing a Pepsi contract.

You can't really argue with Lolly, given the present situation. However, my outlook remains positive.

Good luck with your research. 👍

The Oak bloke has just published an article regarding disconnects;

https://theoakbloke.substack.com/p/three-disconnects

TEK get a mention in the footnote.

Morning Sea,

The LUCY SP finished down on Friday, which might explain the little dip.

I think the NAV/SP disconnect will prevail until the next meaningful news, i.e. a contract worth real money!!

Sold out signs are up;

https://lucyd.co/collections/sunglasses-collection

Https://x.com/Skyline_CCG/status/1797663050943680644

This news is pertinent to the CHK1 thread;

https://www.theguardian.com/society/article/2024/jun/02/drug-pembrolizumab-melts-away-tumours-could-replace-surgery-for-bowel-cancer-say-doctors

Pembrolizumab (Keytruda) is, I believe, a CHK1 inhibitor.

Oddly, (regarding SAR), PM2022 focuses on their finances instead of the Science.

This is precisely the opposite of his VAL viewpoint, in which he extols the science, whilst ignoring the precarious financial position.

The current BOD have proved they are incapable of developing the Valirx pipeline. Change is needed.

I'm fully expecting Cox to have a snidey dig at shareholders tomorrow.

I had a little chuckle at their rather ambitious criteria for changing accounting standards;

"We will remain an emerging growth company until the earliest to occur of: (i) our reporting $1.235 billion or more in annual gross revenues; (ii) the end of fiscal year 2028; (iii) our issuance, in a three year period, of more than $1 billion in non-convertible debt; and (iv) the end of the fiscal year in which the market value of our common stock held by non-affiliates exceeded $700 million on the last business day of our second fiscal quarter."

$700,000,000 MCAP!! That'll do me. 🤣

For the resale of up to 10,173,782 shares.

https://tinyurl.com/59s2r75d

Also included is a detailed appraisal of Lucy's business plan along with current and future prospects/financials.

There is a lot of detail, so probably Sunday night reading!! 🤪

Perhaps you could ask why Valirx can't monetise any legacy asset?

VAL401 really is dead in the water (see link)

(although, it's great news for NSCLC patients);

https://www.theguardian.com/society/article/2024/may/31/trial-results-for-new-lung-cancer-drug-are-off-the-charts-say-doctors

Great stuff Sea, very exciting - the next meme stock!! Could do wonders for sales with increased awareness of the glasses.

I might even chuck in a few grand, if it dips again.

LUCY trading 10-15% higher in premarket, can't find any rumour/news that supports an upward move.

She could be in for another volatile day. 😉